Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytomegalovirus-induced T cell responses accelerate Alzheimer's disease progression in mice.

Brain : a journal of neurology·2026
Same author

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events.

Journal for immunotherapy of cancer·2026
Same author

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.

The New England journal of medicine·2025
Same author

Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial.

medRxiv : the preprint server for health sciences·2025
Same author

Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Aug 25, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.0K

PI3K Isoform Immunotherapy for Solid Tumours.

Jake Scott1, Lauren Rees1, Awen Gallimore1

  • 1Division of Infection and Immunity, Cardiff University School of Medicine, SIURI, Cardiff, C14 4XN, UK.

Current Topics in Microbiology and Immunology
|October 15, 2022
PubMed
Summary

Novel immunotherapies targeting phosphoinositide-3-kinase (PI3K) isoforms in immune cells can enhance anti-tumour T cell responses. Inhibiting PI3Kδ and PI3Kγ in specific cells shows promise for controlling tumour burden and improving cancer treatment efficacy.

Keywords:
CD8+ T cellImmunotherapyMyeloid-derived suppressor cellRegulatory T cellTumourTumour-associated macrophage

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.2K

Related Experiment Videos

Last Updated: Aug 25, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.2K

Area of Science:

  • Immunology and Cancer Research
  • Molecular and Cellular Biology
  • Pharmacology

Background:

  • Current immunotherapies often fail to eradicate tumors, necessitating the development of more effective treatments.
  • The phosphoinositide-3-kinase (PI3K) pathway is crucial for cell signaling, with specific isoforms (PI3Kδ and PI3Kγ) expressed in immune cells.
  • Regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) rely on PI3Kδ and PI3Kγ for survival and function.

Purpose of the Study:

  • To explore the potential of inhibiting specific PI3K isoforms to enhance anti-tumour immune responses.
  • To discuss how targeting PI3Kδ and PI3Kγ in immunosuppressive cells can unleash CD8+ T cell-mediated anti-tumour activity.
  • To review combination immunotherapy strategies involving PI3K inhibitors and immune checkpoint blockade.

Main Methods:

  • Review of scientific literature on PI3K signaling in immune cells and its role in cancer.
  • Discussion of preclinical and clinical data regarding PI3K isoform-specific inhibitors.
  • Analysis of immune response modulation through targeted PI3K inhibition.

Main Results:

  • Inhibition of PI3Kδ in Tregs and MDSCs, and PI3Kγ in TAMs, can reduce immunosuppression and promote anti-tumour immunity.
  • Targeting these PI3K isoforms can lead to enhanced CD8+ T cell responses and control of tumor burden.
  • Combination therapies, particularly with immune checkpoint inhibitors, show potential to potentiate treatment efficacy.

Conclusions:

  • Targeting specific PI3K isoforms represents a promising strategy for developing novel cancer immunotherapies.
  • Understanding the immune response to PI3K inhibition is critical for identifying treatment correlates and overcoming resistance.
  • PI3K isoform-specific inhibitors are advancing in clinical trials for solid tumors, offering new therapeutic avenues.